Drug intelligence / Profile preview

PAR1 CAR-T cells

Development stage: Preclinical
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

PAR1 CAR-T cells are a form of CAR-T cell therapy in which a patient's own T cells are genetically engineered to express a chimeric antigen receptor (CAR) that recognizes PAR1, also known as Protease-activated receptor 1, a target antigen associated with certain cancers. The modified T cells are expanded in vitro and then infused back into the patient, enabling the immune cells to specifically recognize and kill cancer cells expressing PAR1. This is a cell-based immunotherapy and represents a modality within the class of CAR-T cell therapies designed to harness and direct the patient’s immune system against tumor cells[1][3][5][7].

Targets

F2R (Protease-activated receptor 1)

Beyond the preview

Go deeper on PAR1 CAR-T cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PAR1 CAR-T cells.

Explore the full profile